1,25-dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages E572-E582

  Al Hendy, Ayman ^a   Diamond, Michael P ^a   El Sohemy, Ahmed ^b   Halder, Sunil K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; ESTROGEN RECEPTOR ALPHA; NUCLEAR RECEPTOR COACTIVATOR 2; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; RETINOID X RECEPTOR ALPHA; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; DIHYDROXY-VITAMIN D3; ESTROGEN RECEPTOR ALPHA, HUMAN; PROGESTERONE RECEPTOR; VITAMIN D;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; TUMOR CELL LINE; UTERUS MYOMA; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; LEIOMYOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; UTERUS CANCER;

CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LEIOMYOMA; MYOMETRIUM; RECEPTORS, CALCITRIOL; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; VITAMIN D;

EID: 84927611276     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4011     Document Type: Article

References (50)

1. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589-1592.
2. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am. 2006;33(1):59-67.
3. Payson M, Leppert P, Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am. 2006;33(1):1-11.
4. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol. 1980;55(1):20-24.
5. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989;160(3):637-641.
6. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172:14-18.
7. Baird DD, Dunson DB. Whyis parity protective for uterine fibroids? Epidemiology. 2003;14(2):247-250.
8. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. AmJ Clin Nutr. 2002;76(1):187-192.
9. Sabry M, Halder SK, Allah AS, Roshdy E, Rajaratnam V, Al-Hendy A. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health. 2013;5:93-100.
10. Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin D and the risk of uterine fibroids. Epidemiology. 2013;24(3):447-453.
11. Paffoni A, Somigliana E, Vigano' P, et al. Vitamin D status inwomen with uterine leiomyomas. J Clin Endocrinol Metab. 2013;98(8):E1374-E1378.
12. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin Dreceptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13(3):325-349.
13. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1, 25-dihydroxyvitamin D3. Endocrinology. 1995;136(1):20-26.
14. Campbell MJ, Reddy GS, Koeffler HP. Vitamin D 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem. 1997;66(3):413-425.
15. Halder SK, Goodwin JS, Al-Hendy A. 1, 25-Dihydroxyvitamin D3 reduces TGF-β3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96(4):E754-E762.
16. Halder SK, Sharan C, Al-Hendy A. 1, 25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86(4):116.
17. Halder SK, Sharan C, Al-Hendy O, Al-Hendy A. Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci. 2014;21(9):1108-1119.
18. Halder SK, Osteen KG, Al-Hendy A. Vitamin D 3 in hibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28(9):2407-2416.
19. Halder SK, Osteen KG, Al-Hendy A. 1, 25-Dihydroxyvitamin D3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013;89(6):150.
20. Andersen J, DyReyes VM, Barbieri RL, Coachman DM, Miksicek RJ. Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures. J Soc Gynecol Investig. 1995;2(3):542-551.
21. Walker CL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res. 2002;57:277-294.
22. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004;10(3):207-220.
23. Nilsson S, Mäkelä S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81(4):1535-1565.
24. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74(5):311-317.
25. Safe S. Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001;62:231-252.
26. Curtis SW, Washburn T, Sewall C, et al. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA. 1996;93(22):12626-12630.
27. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab. 2002;13(8):349-354.
28. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19(8):1951-1959.
29. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835-839.
30. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J. Comparative effects of 1, 25 (OH) 2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat. 1997;42(1):31-41.
31. Carney SA, Tahara H, Swartz CD, et al. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest. 2002;82(6):719-728.
32. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95(1):247-253.
33. Wei J, Chiriboga L, Mizuguchi M, Yee H, Mittal K. Expression profile of tuberin and some potential tumorigenic factors in 60 patients with uterine leiomyomata. Mod Pathol. 2005;18(2):179-188.
34. Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B, Smith SK. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod. 1997;12(4):815-822.
35. Englund K, Blanck A, Gustavsson I, et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998;83(11):4092-4096.
36. Wang L, Huang H, Liu D, et al. Evaluation of 14-3-3 protein family levels and associated receptor expression of estrogen and progesterone in human uterine leiomyomas. Gynecol Endocrinol. 2012;28(8):665-668.
37. Shaik NA, Lone WG, Khan IA, Rao KP, Kodati VL, Hasan Q. Enhanced transcription of estrogen receptor α and mitochondrial cytochrome b genes in uterine leiomyomas. Gynecol Endocrinol. 2011;27(12):1094-1098.
38. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344-1355.
39. Mas A, Cervello I, Gil-Sanchis C, Simón C. Current understanding of somatic stem cells in leiomyoma formation. Fertil Steril. 2014;102(3):613-620.
40. Mehine M, Mäkinen N, Heinonen HR, Aaltonen LA, Vahteristo P. Genomics of uterine leiomyomas: insights from high-throughput sequencing. Fertil Steril. 2014;102(3):621-629.
41. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012;358(2):223-231.
42. Fujimoto J, Hirose R, Ichigo S, Sakaguchi H, Li Y, Tamaya T. Expression of progesterone receptor form A and B mRNAs in uterine leiomyoma. Tumour Biol. 1998;19(2):126-131.
43. Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol. 2011;347:55-60.
44. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB. Regulation of estrogen receptor-α gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem. 1999;75(4):640-651.
45. Swami S, Krishnan AV, Feldman D. 1α, 25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res. 2000;6(8):3371-3379.
46. Peleg S, Nguyen CV. The importance of nuclear import in protection of the vitamin D receptor from polyubiquitination and proteasomemediated degradation. J Cell Biochem. 2010;110(4):926-934.
47. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai MJ. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol. 2003;23(21):7742-7755.
48. Hussein-Fikret S, Fuller PJ, Gargett CE. Expression of steroid receptor coactivators in cultured cells from paired myometrial and fibroid tissues. J Soc Gynecol Investig. 2005;12(6):445-451.
49. Minghetti PP, Norman AW. 1, 25 (OH) 2-vitamin D3 receptors: gene regulation and genetic circuitry. FASEB J. 1988;2(15):3043-3053.
50. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol. 2003;23(11):3763-3773.